BioCentury
ARTICLE | Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

October 3, 2016 7:00 AM UTC

Top-line data from the open-label, international Phase IIIb GARNET trial in 163 treatment-naive patients with chronic HCV genotype 1b infection without cirrhosis showed that once-daily Viekirax ombitasvir/paritaprevir/ritonavir plus twice-daily Exviera dasabuvir without ribavirin for 8 weeks led to an SVR 12 weeks after the end of treatment, the primary endpoint, in 98% of patients. Two patients experienced post-treatment relapse and 1 patient discontinued the study due to noncompliance. ...